Research Triangle Park, N.C. — Drug giants GlaxoSmithKline (NYSE ... Pfizer Chief Executive Officer Jeff Kindler in a joint statement issued to the London Stock Exchange. "With the strength of the companies' current HIV products, as …
while GSK chose to get rid of the well-known brands to focus on its core pharmaceutical business. According to the Managing Director, Suntory Beverage and Food Nigeria, Mr. Chinedum Okereke, takeover procedures with the Nigerian …
Exports grew the fastest for two and a half years in the past quarter, according to a survey by business lobbying group the CBI, as a post-Brexit fall of over 15 per cent in sterling makes UK-made goods more competitive. Overseas orders rose …
"Constructive feedback" about remuneration from shareholders had also played a role, it said. GSK is the fifth largest company traded on the London Stock Exchange and as head of its Consumer Healthcare business Ms Walmsley was …
GlaxoSmithKline is one of the five most valuable companies listed on the stock market. Breaking it up, in the way Mr Woodford is proposing, would mean the company changing radically and is likely to involve a heated conflict between …
Drug developer Biota Holdings Ltd has been advised that the Japanese arm of global pharmaceutical firm GlaxoSmithKline (GSK) will increase its stock of the anti-flu drug Relenza, which Biota has licensed to GSK. GSK in …
"We are pretty certain it's going to work." Tadataka Yamada, head of research at GlaxoSmithKline, says the changes will introduce a range of incentives to mimic the workings of biotech companies, including stock options, royalties on drug …
Source: Images Money via Flickr. While dividends can be the cornerstone to any successful portfolio focused on the long term, not all dividends are created equally. Put plainly, some dividend checks aren't even worth the paper they're printed …
H1N1 swine flu vaccine maker GlaxoSmithKline released its fourth quarter profits ... with the majority of those sales coming in the first quarter of the year. The company’s stock has declined 2.5 per cent over the last 12 months.
On 4 February, GlaxoSmithKline (GSK) announced that it planned to pull ... and private foundations to take stock. But the biggest problem, researchers say, is that there is almost nothing in the pipeline that gives any hope for a …